Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map.
Todhunter-Brown, Alex, Campbell, Pauline, Broderick, Cathryn et al. · Health technology assessment (Winchester, England) · 2025 · DOI
Quick Summary
This study looked at all ME/CFS research published between 2018 and 2023 to see what scientists have been studying and how much research exists on different topics. Researchers found 639 studies involving over 600,000 people with ME/CFS. More than half of the research focused on trying to understand what causes ME/CFS, while fewer studies looked at treatments or how to diagnose the condition. The researchers created an interactive map so patients and doctors can explore what research has been done.
Why It Matters
This comprehensive research map reveals critical gaps in ME/CFS evidence and guides future research priorities. For patients, it highlights that treatment research remains severely underfunded relative to cause research, and demonstrates the inconsistency in how ME/CFS is defined across studies, which may obscure findings. For researchers and funders, it provides strategic evidence that interventional studies and high-quality diagnostic research are significantly underrepresented and require urgent investment.
Observed Findings
Among 639 included studies (~610,000 participants), only 10% used diagnostic criteria requiring postexertional malaise as a mandatory criterion; 24% used single criteria excluding postexertional malaise entirely.
Majority of research (94%) originated from high-income countries, with significant underrepresentation from low- and middle-income regions.
Systematic review quality was poor: 89% had low methodological quality according to AMSTAR 2.
Demographic reporting was substantially incomplete: 16% did not report gender, 74% did not report ethnicity, and 81% did not report disease severity.
Research topics were heavily skewed toward etiology (53%) compared to interventions (26%) and diagnosis/assessment (15%).
Inferred Conclusions
Current ME/CFS research definitions remain inconsistent and often exclude postexertional malaise, potentially creating heterogeneous populations that complicate evidence synthesis and clinical comparability.
The significant overrepresentation of etiological research relative to intervention and diagnostic research suggests a substantial evidence-to-practice gap and misalignment with patient-identified research priorities.
High-quality systematic reviews are urgently needed to synthesize existing evidence and identify truly rigorous primary studies to inform clinical practice.
Remaining Questions
Why do only 10% of studies mandate postexertional malaise as a diagnostic criterion despite its establishment as a core diagnostic feature in current ME/CFS definitions?
What This Study Does Not Prove
This evidence map does not evaluate the quality or validity of individual primary studies—it only assessed systematic review methodology. It does not determine what the existing evidence actually shows regarding causes, treatments, or diagnostic accuracy. It also does not explain why certain research gaps exist or provide recommendations for specific future studies; it only identifies where research is most scarce.
What explains the stark imbalance between etiological research (53%) and treatment research (26%), and does this reflect funding allocation patterns or scientific feasibility constraints?
How do research findings differ systematically between studies using different diagnostic criteria, and does this heterogeneity account for inconsistent conclusions across the literature?
Why is demographic reporting so poor across ME/CFS research, and what impact does this have on understanding how the disease affects diverse populations?